Article Text

Download PDFPDF

LSO-072 Comparison of COVID-19 vaccination with influenza vaccination in Korean patients with systemic lupus erythematosus: perception, adverse events, and flares from the CIVIL study
  1. Seonghoon Park1,
  2. Seung Cheol Shim2,
  3. Ji Soo Lee3,
  4. Young Ho Lee4,
  5. Seung-Ki Kwok5,
  6. Yong-Gil Kim6,
  7. Yong-Beom Park7,
  8. Sung-Hwan Park5,
  9. Sang-Cheol Bae8,
  10. Chang Hee Suh9,
  11. Yoon-Kyung Sung8,
  12. Shin-Seok Lee10,
  13. Chang-Keun Lee6,
  14. Hye-Soon Lee8,
  15. Seung Min Jung11 and
  16. Hoon-Suk Cha12
  1. 1Internal medicine, Daegu catholic university school of medicine, Republic of Korea
  2. 2Rheumatology, Daejeon Rheumatoid and Degenerative Arthritis Center, Chungnam National University Hospital, Republic of Korea
  3. 3Internal medicine, Ewha Womans University Medical Center, Republic of Korea
  4. 4Rheumatology, Korea University College of Medicine, Republic of Korea
  5. 5Internal medicine, Seoul Saint-Mary’s Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea
  6. 6Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea
  7. 7Internal medicine, Institute for Immunology and Immunologic Disease, Yonsei University College of Medicine, Republic of Korea
  8. 8Rheumatology, Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology, Republic of Korea
  9. 9Rheumatology, Ajou University Hospital, Republic of Korea
  10. 10Internal medicine, Chonnam National University Medical School and Hospital, Republic of Korea
  11. 11Internal medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea,, Republic of Korea
  12. 12Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea


Background Vaccines are widely credited for their role in reducing the incidence and the severity of various infections. The aim of the COVID-19 and Influenza Vaccine In Lupus (CIVIL) study was to compare the perception and safety profile between COVID-19 vaccine and influenza vaccine in Korean patients with systemic lupus erythematosus (SLE).

Methods We conducted a cross-sectional study based on a 34-question web-based survey on COVID-19 and influenza vaccination in 207 confirmed SLE patients. Patients were recruited from 12 academic hospitals affiliated with Korean society of SLE research (KSSR) from DEC 2022 to JAN 2023. The primary outcome was the perception of patients and physicians on the vaccines, and the occurrence of side effects including flare.

Results 94.1% of two hundred respondents were females aged in 20’s (19.8%), 30’s (24.3%), 40’s (27.7%), 50’s (16.8%), and 52% was treated more than 10 years. More than 50% of patients were in stable condition for recent 6 months (below 20mm in 100mm visual analogue scale with lower than 10mg prednisolone equivalent dose). COVID-19 vaccine and influenza vaccine were completed in 77.7% and 87.6% of SLE patients, respectively. Reasons for willing not vaccinated included fear of lupus flare (56.3% vs 24.5%), worried about side effects (52.1% vs 26.6%), and not recommended from physicians (35.4% vs 7.4%) on COVID-19 and influenza vaccines, respectively. Adverse events (AEs) occurred much higher in COVID-19 vaccine (65.8%) than influenza vaccine (12.4%). However, only 4.4% of patients experiencing AEs from COVID-19 vaccine required hospitalization. Most common AEs were pain/redness on injection site, myalgia and/or arthralgia, fatigue, febrile sense. 10.3% of patients taking COVID-19 vaccine experienced lupus flare (arthralgia, skin rash, hair loss, and deterioration of proteinuria/laboratory parameter), which lead to medication change or hospitalization.

Conclusions COVID-19 vaccine has a worse perception and higher adverse events compared to influenza vaccine in Korean SLE patients.

  • Systemic lupus erythematosus
  • COVID-19
  • vaccine

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.